Core Viewpoint - Avoro Capital Advisors LLC has reduced its stake in Amicus Therapeutics by 16.5%, indicating a shift in institutional investment sentiment towards the biopharmaceutical company [2]. Institutional Holdings - Avoro Capital Advisors LLC now holds 15,025,000 shares of Amicus Therapeutics after selling 2,975,000 shares, representing about 1.5% of its investment portfolio and making it the 20th largest holding [2]. - Other large investors have also adjusted their positions, with Goldman Sachs increasing its stake by 7.7% to 2,703,577 shares valued at $22,061,000 [3]. - UBS AM increased its stake by 11.9% to 1,072,474 shares valued at $8,751,000 [3]. - Intech Investment Management LLC grew its stake by 37.1% to 170,922 shares valued at $1,395,000 [3]. - Strs Ohio and Bank of Montreal Can acquired new positions valued at approximately $30,000 and $144,000, respectively [3]. Insider Transactions - Insider David Michael Clark sold 25,643 shares at an average price of $11.00, totaling $282,073, resulting in an 8.63% decrease in his position [4]. - CEO Bradley L. Campbell sold 77,926 shares at an average price of $10.86, totaling $846,276.36, leading to a 6.45% decrease in his ownership [4]. - Insiders sold a total of 226,711 shares worth $2,887,822 over the last three months, with insiders owning 2.20% of the stock [4]. Analyst Ratings - Jefferies Financial Group reissued a "hold" rating with a price target of $14.50, down from $16.00 [5][6]. - Weiss Ratings issued a "sell (d-)" rating, while Cantor Fitzgerald downgraded the stock from "overweight" to "hold" with a price target reduction from $21.00 to $14.50 [6]. - The consensus rating for Amicus Therapeutics is "Hold" with an average target price of $15.39, with three analysts rating it as a Buy, nine as Hold, and one as Sell [6]. Stock Performance - Amicus Therapeutics shares opened at $14.37, with a market cap of $4.51 billion and a price-to-earnings ratio of -179.63 [7]. - The stock has a 12-month low of $5.51 and a high of $14.39, with a quick ratio of 1.88 and a current ratio of 2.84 [7]. Earnings Results - The company reported an EPS of $0.10 for the last quarter, missing the consensus estimate of $0.13 by $0.03 [8]. - Revenue for the quarter was $185.21 million, slightly above analyst estimates of $185.00 million, representing a year-over-year increase of 23.7% [8]. Company Profile - Amicus Therapeutics focuses on developing treatments for rare and orphan diseases, specializing in pharmacological chaperones and gene therapy for lysosomal storage disorders [9]. - The company's lead product, Galafold (migalastat), is approved for treating Fabry disease in patients with amenable genetic variants [10].

Core Insights - Amicus Therapeutics reported adjusted earnings of 10 cents per share for Q4 2025, missing the Zacks Consensus Estimate of 13 cents, but showing an increase from 9 cents per share in the same quarter last year [1][6] Financial Performance - Revenues for Q4 totaled $185.2 million, reflecting a 24% year-over-year increase on a reported basis and a 20% increase at constant exchange rates, surpassing the Zacks Consensus Estimate of $180 million [2][6] - Galafold sales reached $150.2 million, up 14% year over year at constant exchange rates, although it fell short of the Zacks Consensus Estimate of $157 million [4] - Sales of the newly approved combo drug Pombiliti + Opfolda amounted to $35 million, marking a 51% year-over-year increase at constant exchange rates, slightly exceeding the Zacks Consensus Estimate of $34.8 million [4][6] Yearly Overview - For the full year 2025, Amicus generated revenues of $634.2 million, a 17% increase year over year at constant exchange rates, with adjusted earnings of 31 cents per share compared to 24 cents per share in the previous year [8] Acquisition Details - BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus for $14.50 per share in a cash deal totaling $4.8 billion, expected to close in Q2 2026 [9] - Post-acquisition, BioMarin will integrate Galafold and Pombiliti into its commercial portfolio and acquire exclusive U.S. rights to the late-stage pipeline drug DMX-200 [10] Market Performance - Over the past six months, Amicus shares have increased by 91.7%, significantly outperforming the industry average rise of 22.8% [3] - Adjusted operating expenses rose by 17% to $114.2 million in Q4 2025, while cash, cash equivalents, and marketable securities totaled $293.5 million as of December 31, 2025, up from $263.8 million as of September 30, 2025 [7]

Financial Performance - Net product sales increased by $105.9 million to $634.2 million in 2025, driven by growth in Galafold and Pombiliti + Opfolda, along with a favorable foreign currency impact of $13.5 million [326]. - Gross profit for 2025 was $561.3 million, up from $475.4 million in 2024, reflecting an increase of $85.9 million [326]. - The net loss attributable to common stockholders improved to $27.1 million in 2025 from $56.1 million in 2024, a reduction of $29 million [326]. Expenses - Research and development expenses rose to $135.8 million in 2025, primarily due to a $30 million upfront license payment to Dimerix for the DMX-200 drug candidate [328]. - Selling, general, and administrative expenses increased by $60.1 million, mainly due to higher personnel costs and legal fees related to intellectual property litigation and the Merger Agreement with BioMarin [329]. Cash and Securities - Cash, cash equivalents, and marketable securities totaled $293.5 million as of December 31, 2025 [339]. - Net cash provided by operating activities was $33.1 million in 2025, reflecting a net loss adjusted for non-cash expenses and an increase in operating assets and liabilities [340]. - The company has $164.2 million available under its at-the-market equity program, although it is currently prohibited from issuing additional shares due to the Merger Agreement [337]. Mergers and Agreements - The company entered into a Merger Agreement with BioMarin, where shareholders will receive $14.50 per share in cash upon completion [323]. - An exclusive license agreement with Dimerix for DMX-200 includes potential milestone payments totaling up to $590 million, along with tiered royalties on net sales [322]. Debt and Commitments - As of December 31, 2025, remaining maturities on the Senior Secured Term Loan due 2029 were $498.1 million [348]. - The company has binding minimum purchase and manufacturing commitments totaling $218.8 million as of December 31, 2025, with $195.7 million expected in 2026 [351]. Interest Rates and Currency Fluctuations - A hypothetical 100 basis point increase or decrease in the average interest rate on variable rate debts would result in a $4.1 million change in interest expense as of December 31, 2025 [356]. - A near-term 10% fluctuation of the U.S. dollar to GBP exchange rate could result in a potential change in the fair value of net GBP denominated assets and liabilities of approximately $48.6 million [357]. - The annual average variable interest rate for variable rate debts during the year ended December 31, 2025 was 10.7% [356]. Future Outlook - The company expects to incur significant costs due to research and development expenses, including clinical trials, which will impact future capital requirements [346]. - The company may seek additional funding through public or private financings if the Merger with BioMarin is not consummated [347]. Off-Balance Sheet Arrangements - The company has no off-balance sheet arrangements as of December 31, 2025 and 2024 [352].

Revenue Performance - Total revenue for 2025 was $634.2 million, reflecting a 17% year-over-year increase at constant exchange rates (CER) and a currency tailwind of approximately $14 million[2] - Fourth quarter total revenues reached $185.2 million, up 24% year-over-year, or 20% at CER[2] - Galafold net product sales for 2025 were $521.7 million, a 14% increase year-over-year, or 12% at CER[4] - Pombiliti + Opfolda net product sales for 2025 were $112.5 million, representing a 60% year-over-year increase, or 56% at CER[4] - Net product sales increased to $634.2 million in 2025, up 20% from $528.3 million in 2024 and 59% from $399.4 million in 2023[22] Financial Performance - Total GAAP operating expenses for 2025 were $528.5 million, a 17% increase compared to $450.5 million in 2024[4] - GAAP net loss for 2025 was $27.1 million, or $0.09 per share, compared to a net loss of $56.1 million, or $0.18 per share, in 2024[4] - Non-GAAP net income for 2025 was $96.8 million, or $0.31 per share, compared to $73.9 million, or $0.24 per share, in 2024[4] - The net loss attributable to common stockholders narrowed to $27.1 million in 2025, compared to a loss of $56.1 million in 2024[22] - Non-GAAP net income for 2025 was $96.8 million, compared to $73.9 million in 2024, reflecting a significant improvement[28] Cash and Assets - Cash position increased to $294 million at the end of 2025, up from $250 million at the end of 2024[4] - Cash and cash equivalents increased slightly to $214.0 million in 2025 from $213.8 million in 2024[24] - Total assets grew to $949.9 million in 2025, up from $785.0 million in 2024, indicating strong financial health[24] - Accounts receivable increased to $115.3 million in 2025, up from $101.1 million in 2024, indicating growth in sales and customer demand[24] Expenses - Total operating expenses rose to $528.5 million in 2025, an increase of 17% from $450.5 million in 2024[22] - Research and development expenses were $135.8 million in 2025, up 24% from $109.4 million in 2024[22] Acquisition and Guidance - Proposed acquisition by BioMarin is expected to close in Q2 2026, with a total equity value of approximately $4.8 billion[12] - Amicus will not provide financial guidance for 2026 due to the pending acquisition[8]

Core Insights - Amicus Therapeutics reported total revenues of $634.2 million for the full year 2025, reflecting a year-over-year growth of 17% at constant exchange rates (CER) and a currency tailwind of approximately $14 million [3][4][6] - The company is in the process of being acquired by BioMarin Therapeutics for $14.50 per share in an all-cash transaction, expected to close in Q2 2026, subject to regulatory approvals and other customary conditions [5][7] Financial Performance - Total revenues for Q4 2025 were $185.2 million, representing a 24% increase year-over-year, or 20% at CER [3][4] - Galafold® net product sales for 2025 were $521.7 million, a 14% increase year-over-year, or 12% at CER, while Q4 sales were $150.2 million [6] - Pombiliti® + Opfolda® net product sales for 2025 reached $112.5 million, marking a 60% increase year-over-year, or 56% at CER, with Q4 sales of $35.0 million [6] - Total GAAP operating expenses for 2025 were $528.5 million, up 17% from $450.5 million in 2024, while non-GAAP operating expenses increased by 24% to $431.9 million [6][19] - The company reported a GAAP net loss of $27.1 million for 2025, an improvement from a loss of $56.1 million in 2024 [6][19] Cash Position - Cash, cash equivalents, and marketable securities increased to $293.5 million as of December 31, 2025, compared to $249.9 million at the end of 2024, reflecting a $44 million increase [6][19] Corporate Updates - The acquisition agreement with BioMarin has been unanimously approved by both companies' Boards of Directors, and Amicus' Board has recommended that stockholders vote to adopt the agreement [5][7] - The transaction is subject to regulatory clearances and stockholder approval, with an estimated total equity value of approximately $4.8 billion [7]

Group 1 - Amicus Therapeutics Inc. (NASDAQ:FOLD) is identified as one of the 13 stocks with high upside potential, with a price target maintained at $14.50 by TD Cowen analyst Ritu Baral [1][2] - The company's fourth-quarter and full-year 2025 total product revenue slightly exceeded expectations, driven by strong performance of the Fabry disease medication Galafold, while Pompe disease medication revenues aligned with broader Wall Street expectations [1] - The strategic landscape for Amicus is shaped by BioMarin's agreement to acquire the company for $14.50 per share, with the deal expected to close by Q2 2026, pending shareholder and regulatory approvals [2] Group 2 - Amicus Therapeutics focuses on discovering, developing, and delivering medicines for individuals with metabolic diseases [3] - Despite the potential of Amicus as an investment, certain AI stocks are considered to offer greater upside potential with less downside risk [4]

Industry Overview - The fourth-quarter 2025 reporting season for the Medical sector is nearing its final stretch, with only a few pharma and biotech companies left to report [1] - As of February 11, 73.3% of companies in the Medical sector, representing 91% of the sector's market capitalization, reported quarterly earnings, with 86.4% exceeding both earnings and sales estimates [2][10] - Overall, fourth-quarter earnings in the medical sector are expected to decrease by 0.6%, while sales are projected to rise by 10.4% compared to the previous year [4] Company Performance Johnson & Johnson - Reported strong fourth-quarter results, beating estimates for both earnings and sales [3] Novartis - Beat earnings estimates but faced revenue pressure due to generic competition for key drugs like Entresto and Promacta [3] Bristol Myers Squibb - Beat both earnings and sales estimates and issued encouraging guidance [3] Gilead Sciences - Earnings exceeded both top and bottom lines, supported by higher sales of HIV and Liver Diseases drugs [3] Bausch Health - Mixed performance with two earnings beats and two misses in the last four quarters, delivering a four-quarter average negative surprise of 6.26% [5] - Scheduled to report on February 18, with an Earnings ESP of -8.84% and a Zacks Rank 3 [7] Amicus Therapeutics - Disappointing earnings track record with three misses and one beat in the last four quarters, averaging a negative surprise of 20.21% [8] - Set to be acquired by BioMarin, with its lead drug Galafold showing solid uptake [9] BioMarin Pharmaceutical - Impressive track record, beating earnings estimates in each of the last four quarters with an average surprise of 66.51% [11] - Scheduled to report with an Earnings ESP of -3.23% and a Zacks Rank 3, driven by strong demand for its dwarfism drug Voxzogo [12] Insmed - Poor earnings track record with four consecutive misses, averaging a negative surprise of 20.64% [13] - Scheduled to report on February 19, with an Earnings ESP of +7.01% and a Zacks Rank 3 [14] - Lead drug Arikayce gaining traction, with a new drug approval marking a significant milestone [15] Madrigal Pharmaceuticals - Missed earnings expectations in three of the last four quarters, with an average negative surprise of 17.17% [16] - Scheduled to report on February 19, with an Earnings ESP of -852.37% and a Zacks Rank 4 [16][17]

Core Viewpoint - Investors are expected to focus on Amicus Therapeutics' sales performance and updates regarding its merger with BioMarin Pharmaceutical during the upcoming earnings report for Q4 and full-year 2025 [1][6]. Sales Performance - The Zacks Consensus Estimate for Q4 sales is $179.9 million, with earnings expected at 13 cents per share [1]. - Galafold sales are projected to be a key revenue driver, with estimates for Q4 sales at $157 million, reflecting strong demand and compliance [8]. - The combination therapy Pombiliti + Opfolda is also expected to contribute positively to revenues, following its FDA approval in September 2023 [7][8]. Earnings Estimates - The Zacks Consensus Estimate for 2025 EPS is stable at 35 cents, while the estimate for 2026 is 65 cents [2]. - The earnings surprise history shows Amicus has beaten earnings expectations only once in the last four quarters, with an average negative surprise of 20.21% [4]. Merger Details - BioMarin has agreed to acquire Amicus for $14.50 per share, totaling $4.8 billion, with the deal expected to close in Q2 2026 [9][10]. - Post-acquisition, BioMarin will add Galafold and Pombiliti to its portfolio and gain exclusive U.S. rights to the late-stage drug DMX-200 [10]. Stock Performance - Amicus shares have increased by 104.9% over the past six months, outperforming the industry growth of 23.8% [11]. - The stock is currently trading at a price-to-sales (P/S) ratio of 7.42, which is higher than the industry average of 2.46, but below its five-year mean of 8.72 [14][15]. Investment Outlook - The acquisition by BioMarin is seen as a potential catalyst for value realization beyond organic sales growth, with optimism surrounding the strong sales of marketed products [16]. - Despite concerns regarding competition and reliance on Galafold, the company is expected to maintain growth potential, making it advisable for current investors to hold their positions [17][19].

Core Insights - Amicus Therapeutics presented new data on Galafold and POMBILITI + OPFOLDA at the 22nd Annual WORLDSymposium 2026, highlighting advancements in the treatment of Fabry disease and late-onset Pompe disease [1][2] Fabry Disease - Galafold (migalastat) is an oral pharmacological chaperone for treating Fabry disease in adults with amenable GLA variants, stabilizing dysfunctional enzymes to clear disease substrates [8] - Approximately 35 to 50 percent of individuals with Fabry disease may have amenable GLA variants, with variability based on geography [8] - Oral presentations include real-world effectiveness of migalastat versus enzyme replacement therapy in treatment-naïve patients and long-term outcomes from the followME Pathfinders registry [3][4] Pompe Disease - POMBILITI + OPFOLDA is a two-component therapy for late-onset Pompe disease, combining cipaglucosidase alfa and miglustat to enhance enzyme uptake and activity [12] - The therapy is indicated for adult patients weighing ≥40 kg who are not improving on current enzyme replacement therapy [13] - Presentations include 208-week outcomes of cipaglucosidase alfa plus miglustat in patients with late-onset Pompe disease, focusing on muscle function and pulmonary function [6][6] WORLDSymposium - WORLDSymposium serves as a platform for researchers, clinicians, and patient advocacy groups to share the latest discoveries related to lysosomal diseases [16] - The symposium features presentations on both basic science and clinical trials, emphasizing advancements in the understanding and treatment of lysosomal diseases [16] Company Overview - Amicus Therapeutics is a global biotechnology company focused on developing transformative medicines for rare diseases, with a strong commitment to patient care [17]

Core Insights - Amicus Therapeutics, Inc. (NASDAQ:FOLD) is recognized as one of the best biotech stocks under $20, primarily due to its innovative treatments for rare diseases [1] - Jefferies downgraded FOLD from Hold to Buy and reduced the price target from $16 to $14.50, reflecting a cautious outlook despite takeover interest [1][2] - BioMarin announced plans to acquire Amicus Therapeutics for $14.50 per share, valuing the company at approximately $4.8 billion, which includes two marketed therapies generating significant revenue [2] Company Overview - Amicus Therapeutics focuses on developing and commercializing treatments for rare and orphan diseases, with a pipeline that includes therapies for genetic and metabolic disorders such as Fabry disease [3] - The company leverages precision science and patient-centric solutions to enhance long-term health outcomes for patients [3] Financial Performance - The combined revenue from Amicus's marketed therapies, Galafold and Pombiliti + Opfolda, reached $599 million over the past four quarters, indicating strong market performance [2]